- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01971099
Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder
January 13, 2016 updated by: Selmo Geber, Federal University of Minas Gerais
Hypoactive Sexual Desire Disorder (HSDD) is the most prevalent female sexual dysfunction in society and is strongly linked to the quality of life of women.
The androgen hormones decline over age in the premenopausal period, which occurs around 20 years.
Tribulus terrestris is a plant native to India, recommended in the treatment of infertility, low libido and impotence.
Its main active ingredient is the protodioscin, which has been attributed to an increase in testosterone levels and improved sexual function.
The aim of this study is to evaluate the effects of Tribulus Terrestris in premenopausal women with HSDD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30130100
- Hospital das Clínicas - Universidade Federal de Minas Gerais
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- regular menstrual cycle
- with no use of hormonal contraception within the last 3 months
- without any medication, drugs or alcohol.
- Healthy patients without systemic or psychiatric disease
Exclusion Criteria:
Patients with amenorrhea and/or pregnant.
- Patients who underwent bilateral oophorectomy.
- Patient smoker (10 cigarettes per day).
- Patients with blood pressure > 160/90 mm Hg.
- Patient with breast or endometrial carcinoma.
- Patients with a history of myocardial infarction.
- Patient with Diabetes.
- Patient with vaginal bleeding from any source.
- Patients with hepatic injury.
- Patients with active thrombophlebitis or thromboembolic disorders recent
- Patients with interpersonal relationship problems with your relationship or partner
- Patients with sexual problems from your partner
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tribulus Terrestris
patients will use Tribulus terrestris (750 mg/day) during 120 days
|
patients will use 750mg/day of tribulus terrestris
Other Names:
|
Placebo Comparator: Placebo
patients will use placebo for 120 days
|
patients will take one pill a day (the same shape of the drug)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sexual Desire
Time Frame: 120 days
|
we will use the "Quotient Sexual - Version Feminine (QS-F) brazilian questionary to make the evaluation
|
120 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serum levels of prolactin and thyroid-stimulating hormone (TSH)
Time Frame: 120 days
|
blood test
|
120 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serum levels of testosterone and sex hormone-binding globulin (SHBG)
Time Frame: 120 days
|
blood test
|
120 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
October 23, 2013
First Submitted That Met QC Criteria
October 28, 2013
First Posted (Estimate)
October 29, 2013
Study Record Updates
Last Update Posted (Estimate)
January 14, 2016
Last Update Submitted That Met QC Criteria
January 13, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TTM1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoactive Sexual Desire Disfunction
-
University of British ColumbiaCompletedHypoactive Sexual Desire Disorder (HSDD)Canada
-
Warner ChilcottCompletedHypoactive Sexual Desire Disorder (HSDD)United States, Australia, Canada
-
Ivix LLXCompletedHypoactive Sexual Desire Disorder (HSDD)Russian Federation
-
Ivix LLXCompletedHypoactive Sexual Desire Disorder(HSDD)Russian Federation
-
EndoCeutics Inc.AMAG Pharmaceuticals, Inc.WithdrawnHypoactive Sexual Desire Disorder (HSDD)United States
-
S1 Biopharma, Inc.CompletedHypoactive Sexual Desire Disorder (DSM-IV-TR Defined) | Sexual Interest/Arousal Disorder (DSM-5 Defined)United States
-
Bezmialem Vakif UniversityUnknownMenopause | Hypoactive Sexual Desire Disorder | Sexual Desire DisorderTurkey
-
TriHealth Inc.TriHealth Medical Education Research FundCompletedHypoactive Sexual Desire Disorder (HSDD) | Low Libido | Female Sexual Dysfunction (FSD)United States
-
Kwang Dong Pharmaceutical co., ltd.RecruitingHypoactive Sexual Desire DisorderKorea, Republic of
-
Warner ChilcottCompletedHypoactive Sexual Desire DisorderUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States